Zacks Research Issues Positive Estimate for Integer Earnings

Integer Holdings Co. (NYSE:ITGR - Free Report) - Investment analysts at Zacks Research raised their Q2 2025 earnings per share estimates for shares of Integer in a research note issued on Thursday, March 13th. Zacks Research analyst D. Dey now expects that the medical equipment provider will earn $1.44 per share for the quarter, up from their prior estimate of $1.43. The consensus estimate for Integer's current full-year earnings is $6.01 per share. Zacks Research also issued estimates for Integer's Q3 2025 earnings at $1.57 EPS, FY2025 earnings at $5.98 EPS, Q1 2026 earnings at $1.59 EPS, Q2 2026 earnings at $1.54 EPS, FY2026 earnings at $6.58 EPS and FY2027 earnings at $7.15 EPS.

A number of other brokerages have also recently issued reports on ITGR. Truist Financial upped their target price on Integer from $147.00 to $163.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. Citigroup increased their price target on Integer from $130.00 to $145.00 and gave the company a "neutral" rating in a research note on Wednesday, December 11th. KeyCorp increased their price target on Integer from $144.00 to $154.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Oppenheimer lowered Integer from an "outperform" rating to a "market perform" rating in a research report on Friday, February 21st. Finally, Benchmark upped their target price on Integer from $140.00 to $150.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $149.00.

Remove Ads

Integer Price Performance

ITGR traded down $4.23 on Monday, reaching $116.44. The stock had a trading volume of 386,698 shares, compared to its average volume of 309,127. Integer has a fifty-two week low of $107.11 and a fifty-two week high of $146.36. The firm has a 50-day moving average of $133.30 and a 200-day moving average of $132.53. The company has a current ratio of 2.95, a quick ratio of 2.09 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $3.91 billion, a price-to-earnings ratio of 34.70, a price-to-earnings-growth ratio of 1.72 and a beta of 1.24.

Integer (NYSE:ITGR - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing analysts' consensus estimates of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The business had revenue of $449.50 million for the quarter, compared to analyst estimates of $446.28 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ITGR. Raymond James Financial Inc. bought a new position in Integer in the fourth quarter worth approximately $38,073,000. Capital Research Global Investors lifted its holdings in shares of Integer by 16.0% in the fourth quarter. Capital Research Global Investors now owns 1,410,803 shares of the medical equipment provider's stock valued at $186,960,000 after purchasing an additional 194,895 shares in the last quarter. Artisan Partners Limited Partnership bought a new position in shares of Integer in the fourth quarter valued at approximately $22,775,000. Eagle Asset Management Inc. purchased a new stake in shares of Integer during the third quarter valued at approximately $14,403,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Integer during the fourth quarter valued at approximately $7,889,000. Institutional investors own 99.29% of the company's stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.